Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 4, 2010, Pages 588-596

  Páleníček, Tomáš ^a   Hliňák, Zdeněk ^a   Bubeníková Valešová, Věra ^a   Novák, Tomáš ^a   Horáček, Jiří ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

Author keywords

Locomotion; N,N Diethyllysergamide (LSD); Open field; Prepulse inhibition; Rats; Sex differences

Indexed keywords

LYSERGIDE;

ANIMAL EXPERIMENT; ARTICLE; BODY POSTURE; CONTROLLED STUDY; EXPLORATORY BEHAVIOR; FEMALE; LOCOMOTION; MALE; MOTOR PERFORMANCE; NONHUMAN; OPEN FIELD BEHAVIOR; PREPULSE INHIBITION; RAT; SENSORY GATING; SEX DIFFERENCE; STARTLE REFLEX; WET DOG SHAKES;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; ESTROUS CYCLE; EXPLORATORY BEHAVIOR; FEMALE; LYSERGIC ACID DIETHYLAMIDE; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; SENSORY GATING; SEX CHARACTERISTICS; SEX FACTORS; STARTLE REACTION;

EID: 77952669723     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.02.008     Document Type: Article

References (95)

1. Abel K.M., Allin M.P., Hemsley D.R., Geyer M.A. Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 2003, 44:729-737.
2. Adams L.M., Geyer M.A. A proposed animal model for hallucinogens based on LSD's effects on patterns of exploration in rats. Behav Neurosci 1985, 99:881-900.
3. Adams L.M., Geyer M.A. Effects of DOM and DMT in a proposed animal model of hallucinogenic activity. Prog Neuropsychopharmacol Biol Psychiatry 1985, 9:121-132.
4. Allott K., Redman J. Are there sex differences associated with the effects of ecstasy/3, 4-methylenedioxymethamphetamine (MDMA)?. Neurosci Biobehav Rev 2007, 31:327-347.
5. Andrade T.G., Nakamuta J.S., Avanzi V., Graeff F.G. Anxiolytic effect of estradiol in the median raphe nucleus mediated by 5-HT1A receptors. Behav Brain Res 2005, 163:18-25.
6. Attali G., Weizman A., Gil-Ad I., Rehavi M. Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Res 1997, 756:153-159.
7. Bazzett T.J., Becker J.B. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. Brain Res 1994, 637:163-172.
8. Birzniece V., Johansson I.M., Wang M.D., Backstrom T., Olsson T. Ovarian hormone effects on 5-hydroxytryptamine(2A) and 5-hydroxytryptamine(2C) receptor mRNA expression in the ventral hippocampus and frontal cortex of female rats. Neurosci Lett 2002, 319:157-161.
9. Blanchard D.C., Shepherd J.K., Rodgers R.J., Blanchard R.J. Evidence for differential effects of 8-OH-DPAT on male and female rats in the anxiety/defense test battery. Psychopharmacology (Berl) 1992, 106:531-539.
10. Bosse R., Rivest R., Di Paolo T. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res 1997, 46:343-346.
11. Bubenikova V., Votava M., Horacek J., Palenicek T. Relation of sex and estrous phase to deficits in prepulse inhibition of the startle response induced by ecstasy (MDMA). Behav Pharmacol 2005, 16:127-130.
12. Carroll M.E., Lynch W.J., Roth M.E., Morgan A.D., Cosgrove K.P. Sex and estrogen influence drug abuse. Trends Pharmacol Sci 2004, 25:273-279.
13. Cosgrove K.P., Mazure C.M., Staley J.K. Evolving knowledge of sex differences in brain structure, function, and chemistry. Biol Psychiatry 2007, 62:847-855.
14. Cunha J.M., Masur J. Evaluation of psychotropic drugs with a modified open field test. Pharmacology 1978, 16:259-267.
15. Cyr M., Landry M., Di P.T. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 2000, 23:69-78.
16. Deveney A.M., Waddington J.L. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. Br J Pharmacol 1995, 116:2120-2126.
17. Dhir A., Kulkarni S.K. Antidepressant-like effect of 17beta-estradiol: involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems. Can J Physiol Pharmacol 2008, 86:726-735.
18. Egan C.T., Herrick-Davis K., Miller K., Glennon R.A., Teitler M. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors. Psychopharmacology (Berl) 1998, 136:409-414.
19. Fantegrossi W.E., Reissig C.J., Katz E.B., Yarosh H.L., Rice K.C., Winter J.C. Hallucinogen-like effects of N, N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacol Biochem Behav 2008, 88:358-365.
20. Fink G., Sumner B., Rosie R., Wilson H., McQueen J. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. Behav Brain Res 1999, 105:53-68.
21. Fink G., Sumner B.E., Rosie R., Grace O., Quinn J.P. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell Mol Neurobiol 1996, 16:325-344.
22. Fone K.C., Johnson J.V., Bennett G.W., Marsden C.A. Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats. Br J Pharmacol 1989, 96:599-608.
23. Frankfurt M., McKittrick C.R., Mendelson S.D., McEwen B.S. Effect of 5, 7-dihydroxytryptamine, ovariectomy and gonadal steroids on serotonin receptor binding in rat brain. Neuroendocrinology 1994, 59:245-250.
24. Fu C.H., Abel K.M., Allin M.P., Gasston D., Costafreda S.G., Suckling J., et al. Effects of ketamine on prefrontal and striatal regions in an overt verbal fluency task: a functional magnetic resonance imaging study. Psychopharmacology (Berl) 2005, 183:92-102.
25. Geyer M.A., Light R.K., Rose G.J., Petersen L.R., Horwitt D.D., Adams L.M., et al. A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology (Berl) 1979, 65:35-40.
26. Gouzoulis-Mayfrank E., Heekeren K., Neukirch A., Stoll M., Stock C., Obradovic M., et al. Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 2005, 38:301-311.
27. Grailhe R., Waeber C., Dulawa S.C., Hornung J.P., Zhuang X., Brunner D., et al. Increased exploratory activity and altered response to LSD in mice lacking the 5-HT(5A) receptor. Neuron 1999, 22:581-591.
28. Haleem D.J., Kennett G.A., Curzon G. Hippocampal 5-hydroxytryptamine synthesis is greater in female rats than in males and more decreased by the 5-HT1A agonist 8-OH-DPAT. J Neural Transm Gen Sect 1990, 79:93-101.
29. Hasler F., Grimberg U., Benz M.A., Huber T., Vollenweider F.X. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl) 2004, 172:145-156.
30. Hermle L., Funfgeld M., Oepen G., Botsch H., Borchardt D., Gouzoulis E., et al. Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 1992, 32:976-991.
31. Horowski R. Pharmacological effects of lisuride and their potential role in further research. Lisuride and other dopamine agonists - basic mechanisms and endocrine and neurological effects 1983, 127-139. Raven Press, New York. D.B. Calne, R.J. McDonald, R. Horowski, W. Wuttke (Eds.).
32. Horowski R., Wachtel H. Pharmacological effects of lisuride in rodents mediated by dopaminergic receptors: mechanisms of action and influence of chronic treatment with lisuride 1979, 237-251. Pergamon Press, Oxford, New York. K. Fuxe, D.B. Calne (Eds.).
33. Ikemoto S. Ventral striatal anatomy of locomotor activity induced by cocaine, d-amphetamine, dopamine and D1/D2 agonists. Neuroscience 2002, 113:939-955.
34. Kabes J., Fink Z. Alteration of some patterns of spontaneous behavior in rats after LSD. Act Nerv Super (Praha) 1971, 13:99-100.
35. Kabes J., Fink Z. Spontaneous motor activity and acetylcholine brain metabolism in rats after LSD administration 1969, 73-74. Schwabe, Basel.
36. Kabes J., Fink Z., Roth Z. A new device for measuring spontaneous motor activity-effects of lysergic acid diethylamide in rats. Psychopharmacologia 1972, 23:75-85.
37. Koch M. The neurobiology of startle. Prog Neurobiol 1999, 59:107-128.
38. Krebs-Thomson K., Geyer M.A. The role of 5-HT(1A) receptors in the locomotor-suppressant effects of LSD: WAY-100635 studies of 8-OH-DPAT, DOI and LSD in rats. Behav Pharmacol 1996, 7:551-559.
39. Krebs-Thomson K., Paulus M.P., Geyer M.A. Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors. Neuropsychopharmacology 1998, 18:339-351.
40. Krebs-Thomson K., Ruiz E.M., Masten V., Buell M., Geyer M.A. The roles of 5-HT(1A) and 5-HT (2) receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats. Psychopharmacology (Berl) 2006, 189:319-329.
41. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
42. Kutova M., Fujakova M., Palenicek T., Bubenikova-Valesova V. Srovnání účinku psychedelik mezkalinu a 2C-B vanimálním modelu - role serotoninovỳch 5-HT2 a 5-HT1 receptorů (Comparison of the effects of psychedelics mescaline and 2C-B in animal model - role of serotonin 5-HT2 and 5-HT1 receptors) (Abstract). Psychiatrie 2008, 12:47.
43. Landry M., Di P.T. Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor. Brain Res Mol Brain Res 2003, 112:82-89.
44. Lanfumey L., Hamon M. 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 2004, 3:1-10.
45. Lát J. The analysis of habituation. Acta Neurobiol Exp (Wars) 1973, 33:771-789.
46. Le Saux M., Di Paolo T. Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene. J Psychiatry Neurosci 2005, 30:110-117.
47. Lees J., Hallak J.E., Deakin J.F., Dursun S.M. Gender differences and the effects of ketamine in healthy volunteers. J Psychopharmacol 2004, 18:337-339.
48. Leng A., Ouagazzal A., Feldon J., Higgins G.A. Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol Biochem Behav 2003, 75:281-288.
49. Liechti M.E., Gamma A., Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 2001, 154:161-168.
50. Lyles J., Cadet J.L. Methylenedioxymethamphetamine (MDMA, ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Brain Res Rev 2003, 42:155-168.
51. Marcondes F.K., Bianchi F.J., Tanno A.P. Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol 2002, 62:609-614.
52. Marek G.J., Aghajanian G.K. Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action. Drug Alcohol Depend 1998, 51:189-198.
53. Marek G.J., Aghajanian G.K. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther 1996, 278:1373-1382.
54. Marona-Lewicka D., Nichols D.E. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav 2007, 87:453-461.
55. Marona-Lewicka D., Thisted R.A., Nichols D.E. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology (Berl) 2005, 180:427-435.
56. McCann U.D., Ridenour A., Shaham Y., Ricaurte G.A. Serotonin neurotoxicity after (+/-)3, 4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 1994, 10:129-138.
57. Meehan S.M., Schechter M.D. LSD produces conditioned place preference in male but not female fawn hooded rats. Pharmacol Biochem Behav 1998, 59:105-108.
58. Meyer M.E., Shults J.M. Dopamine D1 receptor family agonists, SK&F38393, SK&F77434, and SK&F82958, differentially affect locomotor activities in rats. Pharmacol Biochem Behav 1993, 46:269-274.
59. Mittman S.M., Geyer M.A. Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology (Berl) 1991, 105:69-76.
60. Monroe R.R., Heath R.G., Mickle W.A., Llewellyn R.C. Correlation of rhinencephalic electrograms with behavior; a study on humans under the influence of LSD and mescaline. Electroencephalogr Clin Neurophysiol 1957, 9:623-642.
61. Nakano Y., Matsuda T., Takuma K., Yoshikawa T., Baba A. Sex difference for tolerance of 5-HT1A receptor-mediated temperature and corticosterone responses in mice. Eur J Pharmacol 1992, 219:339-341.
62. Nichols D.E., Frescas S., Marona-Lewicka D., Kurrasch-Orbaugh D.M. Lysergamides of isomeric 2, 4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N, N-diethyllysergamide (LSD). J Med Chem 2002, 45:4344-4349.
63. Ouagazzal A., Grottick A.J., Moreau J., Higgins G.A. Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 2001, 25:565-575.
64. Padich R.A., McCloskey T.C., Kehne J.H. 5-HT modulation of auditory and visual sensorimotor gating: II. effects of the 5-HT2A antagonist MDL 100, 907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology (Berl) 1996, 124:107-116.
65. 2C receptor SB242084 on rat′s locomotion in animal models of psychosis). Adiktologie 2006, 10:16-19.
66. Palenicek T., Balikova M., Bubenikova-Valesova V., Horacek J. Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose. Psychopharmacology (Berl) 2008, 196:51-62.
67. Palenicek T., Bubenikova-Valesova V., Horacek J. The role of serotonin 5-HT2A/C receptors in the behavioral action of the synthetic drug 2C-B (Abstract). World J Biol Psychiatry 2007, 8:205.
68. Palenicek T., Hlinak Z., Bubenikova-Valesova V., Votava M., Horacek J. An analysis of spontaneous behavior following acute MDMA treatment in male and female rats. Neuro Endocrinol Lett 2007, 28:781-788.
69. Palenicek T., Votava M., Bubenikova V., Horacek J. Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol Behav 2005, 86:546-553.
70. Pranzatelli M.R., Pluchino R.S. The relation of central 5-HT1A and 5-HT2 receptors: low dose agonist-induced selective tolerance in the rat. Pharmacol Biochem Behav 1991, 39:407-413.
71. Reneman L., Booij J., De Bruin K., Reitsma J.B., de Wolff F.A., Gunning W.B., et al. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001, 358:1864-1869.
72. Roth M.E., Cosgrove K.P., Carroll M.E. Sex differences in the vulnerability to drug abuse: a review of preclinical studies. Neurosci Biobehav Rev 2004, 28:533-546.
73. Roubicek J., Srnec J. Experimental psychosis caused by LSD. Cas Lek Cesk 1955, 94:189-195.
74. Schwarz B.E., Sem-Jacobsen C.W., Petersen M.C. Effects of mescaline, LSD-25, and adrenochrome on depth electrograms in man. AMA Arch Neurol Psychiatry 1956, 75:579-587.
75. Seeman P., Guan H.C., Hirbec H. Dopamine D2(High) receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse 2009, 63:698-704.
76. Selye H. Protection against LSD by various steroids. Life Sci 1971, 10:1135-1140.
77. Shah N.S., Hedden M.P. Behavioral effects and metabolic fate of N, N-dimethyltryptamine in mice pretreated with beta-diethylaminoethyl-diphenylpropylacetate (SKF 525-A), improniazid and chlorpromazine. Pharmacol Biochem Behav 1978, 8:351-356.
78. Sipes T.A., Geyer M.A. Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats. Neuropharmacology 1994, 33:441-448.
79. Sipes T.E., Geyer M.A. DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors. Behav Pharmacol 1995, 6:839-842.
80. Sipes T.E., Geyer M.A. DOI disrupts prepulse inhibition of startle in rats via 5-HT2A receptors in the ventral pallidum. Brain Res 1997, 761:97-104.
81. Slikker W., Holson R.R., Ali S.F., Kolta M.G., Paule M.G., Scallet A.C., et al. Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 1989, 10:529-542.
82. Smith S.S. Female sex steroid hormones: from receptors to networks to performance-actions on the sensorimotor system. Prog Neurobiol 1994, 44:55-86.
83. Summer B.E., Fink G. Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol 1995, 54:15-20.
84. Sumner B.E., Fink G. Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain. Brain Res Mol Brain Res 1998, 59:205-214.
85. Sumner B.E., Grant K.E., Rosie R., Hegele-Hartung C., Fritzemeier K.H., Fink G. Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brain. Neurosci Lett 2007, 417:95-99.
86. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001, 156:194-215.
87. Sykes E.A. Mescaline-induced motor impairment in rats, assessed by two different methods. Life Sci 1986, 39:1051-1058.
88. van Oekelen D., Megens A., Meert T., Luyten W.H., Leysen J.E. Role of 5-HT(2) receptors in the tryptamine-induced 5-HT syndrome in rats. Behav Pharmacol 2002, 13:313-318.
89. Vollenweider F.X., Csomor P.A., Knappe B., Geyer M.A., Quednow B.B. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 2007, 32:1876-1887.
90. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F., Babler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 1998, 9:3897-3902.
91. Watts V.J., Lawler C.P., Fox D.R., Neve K.A., Nichols D.E., Mailman R.B. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology (Berl) 1995, 118:401-409.
92. Wishaw I.Q., Haun F., Kolb B. Analysis of behavior in laboratory rodents. Modern techniques in neuroscience 1999, 1243-1275. Springer-Verlag, Berlin, Germany. U. Windhorst, H. Johansson (Eds.).
93. Wolbach A.B., Miner E.J., Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia 1962, 3:219-223.
94. Yamamoto T., Ueki S. The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs. Pharmacol Biochem Behav 1981, 14:89-95.
95. Zhou W., Cunningham K.A., Thomas M.L. Estrogen regulation of gene expression in the brain: a possible mechanism altering the response to psychostimulants in female rats. Brain Res Mol Brain Res 2002, 100:75-83.